Key result
Standard four-drug antituberculosis therapy (isoniazid, rifampin, ethambutol, pyrazinamide) is limited by long treatment duration and poor effectiveness against multidrug-resistant organisms.
Answers are grounded in this paper and cite their sources.
This commentary highlights the limitations of the standard four-drug regimen for pulmonary tuberculosis—specifically long treatment duration and poor efficacy against multidrug-resistant organisms—and notes ongoing research into new antituberculosis agents.
Tuberculosis is an ancient scourge that remains a modern challenge. Despite the availability of good treatment for drug-susceptible disease, an enormous number of deaths still occur worldwide. Although there are many reasons for this disparity, two are related to our current standard four-drug regimen for drug-susceptible pulmonary tuberculosis (isoniazid, rifampin, ethambutol, and pyrazinamide): the duration of treatment is quite long, which makes adherence challenging, and the effectiveness is poor in patients infected with multidrug-resistant organisms. Although antibiotic development has been deprioritized by many organizations, research involving drugs for tuberculosis has remained a bright spot, and many new antituberculosis agents are . . .
No takes yet. Share an insight, caveat, or question.
Eric J. Rubin (2026) conducted an editorial in Pulmonary tuberculosis. New antituberculosis agents vs. Standard four-drug regimen (isoniazid, rifampin, ethambutol, and pyrazinamide) was evaluated. Standard four-drug antituberculosis therapy (isoniazid, rifampin, ethambutol, pyrazinamide) is limited by long treatment duration and poor effectiveness against multidrug-resistant organisms.
Synapse has enriched 10 related papers. Consider them for comparative context: